Middle East and Africa CDMO Market Outlook

The Middle East and Africa (MEA) Contract Development and Manufacturing Organization (CDMO) market is emerging as a vital component of the global pharmaceutical and biotechnology value chain. In 2025, the market was valued at approximately USD 9.95 billion and is projected to grow at a compound annual growth rate (CAGR) of 5.50% during the forecast period of 2026–2035, reaching an estimated value of USD 17.00 billion by 2035.

The growth of the Middle East and Africa CDMO Market is largely driven by the increasing burden of chronic and infectious diseases, particularly cancer, diabetes, and cardiovascular conditions. Governments across the region are actively promoting domestic pharmaceutical manufacturing to reduce reliance on imports and strengthen healthcare systems. This has led to increased investment in local production facilities, research infrastructure, and regulatory frameworks.

CDMOs play a crucial role in supporting pharmaceutical and biotechnology companies by providing services such as drug development, manufacturing, and packaging. By outsourcing these functions, companies can reduce costs, accelerate time-to-market, and focus on core competencies such as research and marketing.

The MEA region is gaining attention as a strategic destination for CDMO services due to its growing healthcare demand, cost advantages, and improving regulatory environment. Countries such as Saudi Arabia, the UAE, and South Africa are leading the development of this market, supported by strong government initiatives and infrastructure development.

Market Trends

The MEA CDMO market is evolving rapidly, influenced by technological advancements, regulatory changes, and shifting industry dynamics.

. Increasing Outsourcing by Pharmaceutical Companies

Pharmaceutical and biopharmaceutical companies are increasingly outsourcing drug development and manufacturing activities to CDMOs to reduce operational costs and improve efficiency. This trend is particularly prominent among small and mid-sized companies with limited in-house capabilities.

. Growth in Biologics and Advanced Therapies

There is a growing focus on biologics, including monoclonal antibodies, vaccines, and gene therapies. CDMOs are investing in capabilities to support large molecule manufacturing and high-potency active pharmaceutical ingredients (HPAPIs).

. Expansion of Local Manufacturing Capabilities

Governments in the MEA region are encouraging local production through incentives, partnerships, and regulatory reforms. This is leading to the establishment of new manufacturing facilities and the expansion of existing ones.

. Integration of Digital Technologies

Digitalization is transforming the CDMO landscape, with the adoption of advanced analytics, automation, and artificial intelligence to improve process efficiency and quality control.

. Focus on Regulatory Compliance and Quality Standards

As the market matures, there is increasing emphasis on meeting international regulatory standards, such as Good Manufacturing Practices (GMP), to ensure product quality and facilitate global market access.

Get a free request sample report

Drivers of Growth

Several key factors are driving the growth of the MEA CDMO market.

. Rising Disease Burden

The increasing prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, is driving demand for pharmaceutical products and, consequently, CDMO services.

. Government Support and Policies

Governments across the region are implementing policies to promote domestic pharmaceutical production, including tax incentives, funding programs, and infrastructure development.

. Cost Advantages

The MEA region offers cost advantages in terms of labor, infrastructure, and operational expenses, making it an attractive destination for outsourcing.

. Growing Pharmaceutical Industry

The expansion of the pharmaceutical and biotechnology sectors in the region is creating demand for CDMO services.

. Increasing Investment in Healthcare Infrastructure

Investments in healthcare facilities, research centers, and manufacturing plants are supporting the growth of the CDMO market.

Market Segmentation

The MEA CDMO market can be segmented based on service type, therapeutic area, end user, and region.

By Service Type

• Contract Manufacturing Organization (CMO):

  • Active Pharmaceutical Ingredient (API) Manufacturing

    • Small Molecule

    • Large Molecule

    • High Potency (HPAPI)

  • Finished Formulation (FDF) Development and Manufacturing

    • Solid Dose Formulation

    • Liquid Dose Formulation

    • Injectable Dose Formulation

  • Secondary Packaging Services

  • Others

• Contract Research Organization (CRO):

  • Pre-Clinical

  • Phase I

  • Phase II

  • Phase III

  • Phase IV

By Therapeutic Area

• Oncological Diseases

• Metabolic Disorders

• Neurological Disorders

• Respiratory Diseases

• Cardiovascular Diseases

• Infectious Diseases

• Others

Oncology represents a significant segment due to the rising incidence of cancer in the region.

By End User

• Pharmaceutical and Biopharmaceutical Companies

• Medical Devices Companies

• Others

By Region

• Saudi Arabia

• UAE

• South Africa

• Nigeria

• Others

Saudi Arabia and the UAE are leading markets due to strong government support and infrastructure development.

Key Players

The MEA CDMO market is characterized by the presence of global and regional players. Key companies include:

• Recipharm AB

• Boehringer Ingelheim

• Patheon Pharma Services (Thermo Fisher Scientific Inc.)

• Pfizer Inc.

• Lonza Group

• Balsam Clinical Research

• WuXi AppTec

• Fareva SA

• FUJIFILM Diosynth Biotechnologies

• Nipro Pharma Corporation

• B. Braun SE

• WuXi Biologics

These companies are focusing on expanding their service offerings, investing in advanced technologies, and forming strategic partnerships to strengthen their market position.

Challenges and Opportunities

Challenges

• Regulatory Complexity:
  Variations in regulatory frameworks across countries can create challenges for companies operating in multiple markets.

• Limited Skilled Workforce:
  A shortage of skilled professionals in certain areas can impact operational efficiency and quality.

• Infrastructure Gaps:
  In some regions, inadequate infrastructure can hinder the development of advanced manufacturing facilities.

• Political and Economic Instability:
  Certain countries in the region face political and economic challenges that can affect investment and market growth.

• Competition from Established Markets:
  MEA CDMOs face competition from well-established markets in North America, Europe, and Asia.

Opportunities

• Expansion of Biologics Manufacturing:
  Growing demand for biologics presents significant opportunities for CDMOs to expand their capabilities.

• Strategic Partnerships:
  Collaborations between global and local companies can enhance technology transfer and market access.

• Investment in Research and Development:
  Increasing focus on R&D can drive innovation and improve competitiveness.

• Growth in Clinical Trials:
  The region offers opportunities for conducting clinical trials due to diverse patient populations.

• Government Initiatives:
  Supportive policies and incentives can accelerate market development.

Market Forecast

The MEA CDMO market is expected to grow steadily over the forecast period, reaching approximately USD 17.00 billion by 2035 at a CAGR of 5.50%.

Key factors influencing the forecast include increasing outsourcing by pharmaceutical companies, rising demand for biologics, and continued government support for domestic manufacturing. The contract manufacturing segment is expected to dominate the market, while the contract research segment is also anticipated to grow significantly.

Regional growth will be led by Saudi Arabia and the UAE, supported by strong infrastructure and policy frameworks. South Africa and Nigeria are also expected to contribute to market expansion due to growing healthcare demand.

Overall, the market outlook is positive, with significant opportunities for growth and innovation in the coming years.

Frequently Asked Questions (FAQs)

1. What is a CDMO?

A Contract Development and Manufacturing Organization (CDMO) provides services to pharmaceutical and biotechnology companies, including drug development, manufacturing, and packaging.

2. What is driving the growth of the MEA CDMO market?

Growth is driven by increasing disease burden, government support, cost advantages, and the expansion of the pharmaceutical industry.

3. Which segment dominates the market?

The contract manufacturing segment, particularly API and finished formulation manufacturing, dominates the market.

4. What are the major challenges in the market?

Challenges include regulatory complexity, limited skilled workforce, infrastructure gaps, and political instability.

5. What is the future outlook for the market?

The market is expected to grow steadily, driven by outsourcing trends, biologics demand, and government initiatives.

Read More Artical:

Spain Yoghurt Market

Australia Luxury Perfume Market

Peru Yoghurt Market

About Us:

Expert Market Research is a global market intelligence and consulting platform by Claight delivering data-driven insights across commodities, chemicals, energy, and industrial markets. We design our research to support businesses, analysts, investors, and procurement teams in understanding price trends, supply-demand dynamics, competitive landscapes, gaining competitive intelligence, benchmarking best practices, and developing long-term market outlooks.

Our robust research methodologies, combined with validated primary and secondary data, ensure accuracy, consistency, and relevance. Our analysis is widely used not only for strategic planning, market-entry assessments, and sourcing decisions, but also for investment evaluation across international markets. Our strong emphasis on transparency, factual reporting, and regular data updates to reflect real-time market conditions always keeps you ahead of the curve.

Media Contact

Company Name: Claight Corporation
Contact Person: Deepanshu Choudhary, Business Consultant
Email: [email protected]
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com